CSPG4 in cancer: multiple roles
- PMID: 20455858
- DOI: 10.2174/156652410791316977
CSPG4 in cancer: multiple roles
Abstract
Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight-Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.
Similar articles
-
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.Clin Cancer Res. 2014 Feb 15;20(4):962-71. doi: 10.1158/1078-0432.CCR-13-2218. Epub 2013 Dec 13. Clin Cancer Res. 2014. PMID: 24334762 Free PMC article.
-
CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.J Natl Cancer Inst. 2010 Oct 6;102(19):1496-512. doi: 10.1093/jnci/djq343. Epub 2010 Sep 17. J Natl Cancer Inst. 2010. PMID: 20852124 Free PMC article.
-
Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.Int J Oncol. 2015 Jul;47(1):81-90. doi: 10.3892/ijo.2015.3010. Epub 2015 May 18. Int J Oncol. 2015. PMID: 25997619 Free PMC article.
-
Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.Proc Jpn Acad Ser B Phys Biol Sci. 2024;100(5):293-308. doi: 10.2183/pjab.100.019. Proc Jpn Acad Ser B Phys Biol Sci. 2024. PMID: 38735753 Free PMC article. Review.
-
CSPG4: a prototype oncoantigen for translational immunotherapy studies.J Transl Med. 2017 Jul 1;15(1):151. doi: 10.1186/s12967-017-1250-4. J Transl Med. 2017. PMID: 28668095 Free PMC article. Review.
Cited by
-
Cancer stem cell markers in head and neck squamous cell carcinoma.Stem Cells Int. 2013;2013:319489. doi: 10.1155/2013/319489. Epub 2013 Mar 3. Stem Cells Int. 2013. PMID: 23533441 Free PMC article.
-
Therapeutic targets of triple-negative breast cancer: a review.Br J Pharmacol. 2015 Sep;172(17):4228-37. doi: 10.1111/bph.13211. Epub 2015 Jul 30. Br J Pharmacol. 2015. PMID: 26040571 Free PMC article. Review.
-
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.Clin Cancer Res. 2014 Feb 15;20(4):962-71. doi: 10.1158/1078-0432.CCR-13-2218. Epub 2013 Dec 13. Clin Cancer Res. 2014. PMID: 24334762 Free PMC article.
-
NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.Leukemia. 2018 Mar;32(3):633-644. doi: 10.1038/leu.2017.294. Epub 2017 Sep 25. Leukemia. 2018. PMID: 28943635 Free PMC article.
-
Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions.Front Oncol. 2022 Nov 14;12:1042766. doi: 10.3389/fonc.2022.1042766. eCollection 2022. Front Oncol. 2022. PMID: 36452484 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous